科罗拉多州

我们是谁

  • 4 月 5, 2022
    BMS-986288单独或与Nivolumab联合治疗晚期实体瘤的免疫疗法研究
  • 4 月 5, 2022
    治疗实体瘤患者的 Pembrolizumab 和重组白细胞介素-12
  • 4 月 5, 2022
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
  • 4 月 5, 2022
    Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
  • 4 月 5, 2022
    KRAS G12C突变晚期结直肠癌患者MRTX849联合西妥昔单抗与化疗的3期研究（KRYSTAL-10）
  • 4 月 5, 2022
    DCC-3014 对晚期肿瘤和腱鞘巨细胞瘤患者的研究
  • 4 月 5, 2022
    MRTX849 治疗 KRAS G12C 基因突变癌症患者的 1/2 期研究 KRYSTAL-1
  • 4 月 5, 2022
    A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
  • 4 月 5, 2022
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
  • 4 月 5, 2022
    Repotrectinib（TPX-0005）对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究